Improving prostate-specific antigen screening

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2491-2492

  Strope, Seth A ^a   Andriole, Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN SPECIFICITY; CANCER SCREENING; EDITORIAL; HUMAN; MORTALITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; EARLY DIAGNOSIS; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; NOTE; PROSTATE TUMOR;

EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77956411578     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.9779     Document Type: Editorial

References (14)

1. Andriole GL, Crawford ED, Grubb III RL, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
2. Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Vickers A, Cronin A, Roobol M, et al: Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: An independent replication. J Clin Oncol 28:2493-2498, 2010
4. King CR, McNeal JE, Gill H, et al: Extended prostate biopsy scheme improves reliability of Gleason grading: Implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 59:386-391, 2004 (Pubitemid 38622590)
5. Freedland SJ, Kane CJ, Amling CL, et al: Upgrading and downgrading of prostate needle biopsy specimens: Risk factors and clinical implications. Urology 69:495-499, 2007 (Pubitemid 46428381)
6. San Francisco IF, DeWolf WC, Rosen S, et al: Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 169:136-140, 2003 (Pubitemid 35461571)
7. Thompson IM, Pauler Ankerst D, Chi C, et al: Prediction of prostate cancer for patients receiving finasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol 25:3076-3081, 2007 (Pubitemid 47218054)
8. Merrill RM, Weed DL, Feuer EJ: The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev 6:763-768, 1997
9. Merrill RM, Weed DL: Measuring the public health burden of cancer in the United States through lifetime and age-conditional risk estimates. Ann Epidemiol 11:547-553, 2001
10. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004 (Pubitemid 41095147)
11. Potosky AL, Davis WW, Hoffman RM, et al: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst Sep 15 96:1358-1367, 2004 (Pubitemid 39406169)
12. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
13. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003 (Pubitemid 36859473)
14. Thompson IM, Chi C, Ankerst DP, et al: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98:1128-1133, 2006 (Pubitemid 44288787)